Digital Health Platform Doctor Anywhere Closes Series C Round to Deepen Southeast Asia Expansion
Digital Health Platform Doctor Anywhere Closes Series C Round to Deepen Southeast Asia Expansion
Healthcare (HC)
Biofourmis Earns FDA’s First-Ever Breakthrough Device Designation for a Novel Digital Therapeutic for Heart Failure
Full Press Release from Biofourmis
BOSTON, July 29, 2021
These 4 Singaporean companies are changing healthcare as we know it
These 4 Singaporean companies are changing healthcare as we know it
MiRXES Secures US$77 Million Series C Funding To Accelerate Multi-Cancer Early Detection Pipeline With Overwhelming Investor Support
MiRXES Secures US$77 Million Series C Funding To Accelerate Multi-Cancer Early Detection Pipeline With Overwhelming Investor Support
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic Codes for New Medicines Through Machine Learning and Next-Generation Combinatorial Genetics
MAY 26, 2021 – SINGAPORE & SAN CARLOS, Calif.–Engine Biosciences (“Engine”) today announced the successful completion of an oversubscribed $43 million Series A funding round. Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions.
Hummingbird Bioscience Raises US$125 Million in Series C Financing
SINGAPORE, May 17, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced the close of its US$125 million Series C financing round.
ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery
SINGAPORE and SAN DIEGO – April 14, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has completed a $14 million fundraising round co-led by new investor EDBI together with existing investors Anzu Partners and University of Tokyo Edge Capital Partners (UTEC).
Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Company concluded an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19 vaccine for the people of Singapore.